High performance of human papillomavirus 16/18/58 genotyping combined with cytology in the initial screening of cervical cancer in China

Background: This study evaluated the diagnostic performance of high-risk human papillomavirus (HR-HPV) genotyping combined with cytological triage for detecting histological high-grade squamous intraepithelial lesions or worse (HSIL+) in women without prior screening history. Methods: A total of 1081 women with abnormal HPV test results underwent cytology testing and colposcopy-guided biopsy. The proportion and risk of HSIL+ positivity were analyzed based on HPV genotype and cytological findings. Results: Among the HR-HPV types, HPV16 was the most prevalent, followed by HPV52 and HPV58. HSIL+ was diagnosed in 286 women (26.5%). HPV16-positive women exhibited the highest incidence of HSIL+ (49.9%), followed by those positive for HPV18 and HPV58. In women with normal cytology (negative for intraepithelial lesion and malignancy (NILM), n = 463), 103 cases of HSIL+ were identified, accounting 36.0% of all HSIL-positive cases. The risk ratios and 95% confidence intervals (CIs) for HSIL+ in women positive for HPV16, HPV18 and HPV58 were 5.84 (95% CI: 2.86–11.92), 2.69 (95% CI: 1.08–6.69), and 3.11 (95% CI: 1.12–8.66), respectively, compared to other HR-HPV types. Multivariate analysis indicated that HPV16/18/58 positivity and cytology atypical squamous cells of undetermined significance or worse (cytology ≥ ASC-US (atypical squamous cells of undetermined significance)) were independent predictors of HSIL or worse. The sensitivity of predicting HSIL or worse was over 90%, and the negative predictive value was 92.0%. Conclusions: The combination of HPV genotyping and cytology demonstrated high diagnostic performance in women without a screening history. In regions with a high prevalence of HPV58, referral for colposcopy or histological examination is warranted for HPV58-positive women to optimize early detection of HSIL.

High-risk human papillomavirus; HPV genotyping; High-grade cervical lesions; Cervical cancer; Initial screening; Diagnostic performance

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Benard VB, Jackson JE, Greek A, Senkomago V, Huh WK, Thomas CC, et al. A population study of screening history and diagnostic outcomes of women with invasive cervical cancer. Cancer Medicine. 2021; 10: 4127–4137.

[3] Alfaro K, Maza M, Cremer M, Masch R, Soler M. Removing global barriers to cervical cancer prevention and moving towards elimination. Nature Reviews Cancer. 2021; 21: 607–608.

[4] Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al.; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. Journal of Lower Genital Tract Disease. 2020; 24: 102–131.

[5] Cuzick J, Adcock R, Kinney W, Castle PE, Robertson M, McDonald RM, et al.; New Mexico HPV Pap Registry Steering Committee. Impact of HPV testing in opportunistic cervical screening: support for primary HPV screening in the United States. International Journal of Cancer. 2023; 153: 83–93.

[6] Demarco M, Egemen D, Raine-Bennett TR, Cheung LC, Befano B, Poitras NE, et al. A study of partial human papillomavirus genotyping in support of the 2019 ASCCP risk-based management consensus guidelines. Journal of Lower Genital Tract Disease. 2020; 24: 144–147.

[7] El-Zein M, Bouten S, Abdrabo LS, Siblini A, Louvanto K, Franco E, et al. Genotyping and cytology triage of high-risk HPV DNA positive women for detection of cervical high-grade lesions. Journal of Lower Genital Tract Disease. 2023; 27: 12–18.

[8] Wang S, Ma QY, Du J, Wei TT, Zhang WX, Wang P, et al. Detecting and genotyping high-risk human papillomavirus among male patients during 2015–2023 in Beijing, China. Emerging Microbes & Infections. 2024; 13: 2313848.

[9] Zhang J, Cheng K, Wang Z. Prevalence and distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia in China: a meta-analysis. Archives of Gynecology and Obstetrics. 2020; 302: 1329–1337.

[10] Zhang H, Zhang S. Prevalence and genotype distribution of human papillomavirus infection among female outpatients in Northeast China: a population-based survey of 110,927 women. Archives of Gynecology and Obstetrics. 2023; 308: 35–41.

[11] Bao HL, Jin C, Wang S, Song Y, Xu ZY, Yan XJ, et al. Prevalence of cervicovaginal human papillomavirus infection and genotypes in the pre-vaccine era in China: a nationwide population-based study. The Journal of Infection. 2021; 82: 75–83.

[12] Zhong F, Li Z, Sun Y, Xiao Y, Li J, Zhou X, et al. HPV genotyping of cervical histologic specimens of 61,422 patients from the largest women hospital in China. Frontiers in Oncology. 2023; 13: 1161631.

[13] Tao X, Zhang H, Zhang H, Xiao Y, Zhong F, Zhou X, et al. The clinical utility of extended high-risk HPV genotyping in risk-stratifying women with L-SIL cytology: a retrospective study of 8726 cases. Cancer Cytopathology. 2022; 130: 542–550.

[14] Gustafson LW, Tranberg M, Christensen PN, Brøndum R, Wentzensen N, Clarke MA, et al. Clinical utility of p16/Ki67 dual-stain cytology for detection of cervical intraepithelial neoplasia grade two or worse in women with a transformation zone type 3: a cross-sectional study. BJOG. 2023; 130: 202–209.

[15] Gajsek US, Dovnik A, Takac I, Ivanus U, Jerman T, Zatler SS, et al. Diagnostic performance of p16/Ki-67 dual immunostaining at different number of positive cells in cervical smears in women referred for colposcopy. Radiology and Oncology. 2021; 55: 426–432.

[16] Dovnik A, Repše Fokter A. The role of p16/Ki67 dual staining in cervical cancer screening. Current Issues in Molecular Biology. 2023; 45: 8476–8491.

[17] Luo H, Lian Y, Tao H, Zhao Y, Wang Z, Zhou J, et al. Relationship between p16/ki67 immunoscores and PAX1/ZNF582 methylation status in precancerous and cancerous cervical lesions in high-risk HPV-positive women. BMC Cancer. 2024; 24: 1171.

[18] Vink FJ, Meijer CJLM, Hesselink AT, Floore AN, Lissenberg-Witte BI, Bonde JH, et al. FAM19A4/miR124-2 methylation testing and human papillomavirus (HPV) 16/18 genotyping in HPV-positive women under the age of 30 years. Clinical Infectious Diseases. 2023; 76: e827–e834.

[19] Huang M, Wang T, Li M, Qin M, Deng S, Chen D. Evaluating PAX1 methylation for cervical cancer screening triage in non-16/18 hrHPV-positive women. BMC Cancer. 2024; 24: 913.

[20] Wentzensen N, Clarke MA, Bremer R, Poitras N, Tokugawa D, Goldhoff PE, et al. Clinical evaluation of human papillomavirus screening with p16/Ki-67 dual stain triage in a large organized cervical cancer screening program. JAMA Internal Medicine. 2019; 179: 881–888.